Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.2352W HIGH $14.68
Volume
6.94 M
Value Traded
17.63 M
Short % Float
23.92%
Days to Cover
9.9
-29.6%Week
-32.52%1 Month
-25.5%3 Month
-12.12%6 Month
-66.72%5 Year
-68%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.03 B
EPS (TTM)
-1.35
P/E Ratio
-
Ent. Value
638.60 M
Total Shares
103.65 M
Float Shares
68.21 M
Insiders
34.19%
Institutions
86.98%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ORIC Catalyst Timeline
Dated clinical, regulatory and corporate events for Oric Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Oric Pharmaceuticals, Inc.
431Total events
17Upcoming
75Tier-1 (high impact)
2020 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Poster PresentationRinzimetostatPresentation
ePoster 1128eP presented at ESMO Congress 2026 with preclinical and translational data for rinzimetostat in prostate cancer
prostate cancersource ↗
◆R&D DayORIC-114Presentation
ORIC conference call and webcast to review enozertinib Phase 1b data at ESMO 2026
first-line NSCLC with EGFR atypical mutationssource ↗
▲Preclinical PoCRinzimetostatPreclinical
Preclinical and mCRPC patient-sample data show rinzimetostat reinforces AR dependence and synergizes with AR inhibition
prostate cancersource ↗
▲Full ResultsORIC-114Clinical Data
Enozertinib Phase 1b data in 1L EGFR atypical NSCLC presented at ESMO 2026
1L EGFR atypical NSCLCsource ↗
●AbstractORIC-114Presentation
Full abstracts of three ESMO 2026 posters publicly available on ESMO Congress website
first-line NSCLC with EGFR atypical mutationssource ↗
▲Partnership / LicenseORIC-259Corporate
ORIC and Cancer Research UK agreement to advance ORIC-259 into clinical development
cancersource ↗
▲Grant / FundingCorporate
ORIC granted inducement stock options and RSUs to six new employees
▲Trial InitiationRinzimetostatTrial
Initiated Himalayas-1 global Phase 3 trial
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Partnership / LicenseRinzimetostatCorporate
Clinical trial collaboration and supply agreement with Bayer for darolutamide
metastatic castration-resistant prostate cancer (mCRPC)source ↗
●End Of Phase 1 MeetingRinzimetostatFDA Meeting
End-of-Phase 1 interactions with FDA and other global health authorities
metastatic castration-resistant prostate cancer (mCRPC)source ↗
●Oral PresentationRinzimetostatPresentation
Presented preclinical data at AACR
prostate cancersource ↗
▲Trial InitiationRinzimetostatTrial
Initiation of Himalayas-1 global Phase 3 registrational trial in mCRPC evaluating rinzimetostat in combination with darolutamide
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Partnership / LicenseRinzimetostatCorporate
Clinical trial collaboration and supply agreement with Bayer for darolutamide supply in Himalayas-1 trial
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆Timing GuidanceORIC-114Presentation
1L EGFR exon 20 insertion monotherapy data and combination data with SC amivantamab in 2H 2026
NSCLCsource ↗
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
◆Topline ReadoutORIC-114Clinical Data
Data readout for 1L EGFR exon 20 combination and 1L EGFR atypical cohorts
NSCLC (1L EGFR exon 20 combination with SC amivantamab and 1L EGFR atypical)source ↗
▲Enrollment CompleteORIC-114Trial
Completed enrollment in Phase 1b trial of enozertinib as single-agent in first-line patients
advanced NSCLC with EGFR exon 20 insertion mutationssource ↗
◆Poster PresentationRinzimetostatPresentation
Poster presentation at AACR 2026: Rinzimetostat efficacy in PRC2 methyltransferase-resistant settings
prostate cancersource ↗
◆Poster PresentationRinzimetostatPresentation
Poster presentation at AACR 2026: Rinzimetostat blockade of PRC2 activity improves response of androgen receptor pathway inhibition across prostate cancer models
prostate cancersource ↗
◆Topline ReadoutORIC-114Clinical Data
Next data update for 1L patients expected mid-2026
NSCLC with EGFR exon 20 mutationssource ↗
◆Timing GuidanceORIC-114Presentation
Next update expected in mid-2026 for 1L NSCLC patients with EGFR exon 20 and PACC mutations
NSCLC with EGFR exon 20 and EGFR PACC mutationssource ↗
◆Topline ReadoutORIC-114Clinical Data
Initial data from Phase 1b combination trial of ORIC-114 with SC amivantamab
advanced NSCLC with EGFR exon 20 insertion mutationssource ↗
▼Program DiscontinuationRinzimetostatCorporate
Rinzimetostat (ORIC-944) program update: similar effectiveness as competing drug, falling short of expectations
prostate cancersource ↗
◆Oral PresentationRinzimetostatPresentation
Combination dose optimization data from Phase 1b trial of rinzimetostat in mCRPC
metastatic castration resistant prostate cancer (mCRPC)source ↗
▲Dose Finding UpdateRinzimetostatTrial
RP3D selected: 400 mg QD rinzimetostat + darolutamide based on exposure-response analysis
metastatic castration-resistant prostate cancer (mCRPC) post-abirateronesource ↗
▲Topline ReadoutRinzimetostatClinical Data
Preliminary efficacy data: landmark 5-month rPFS 84% at RP3D
metastatic castration-resistant prostate cancer (mCRPC) post-abirateronesource ↗
◆Oral PresentationPresentation
Conference call and webcast to discuss rinzimetostat program update
◆Oral PresentationPresentation
ORIC Pharmaceuticals to present at 44th Annual J.P. Morgan Healthcare Conference
◆Timing GuidanceRinzimetostatPresentation
Preliminary dose optimization data expected in Q1 2026
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆Topline ReadoutRinzimetostatClinical Data
Preliminary dose optimization data expected in 1Q 2026
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆Trial InitiationRinzimetostatTrial
Potential initiation of registrational trial for ORIC-944
mCRPCsource ↗
◆Topline ReadoutORIC-114Clinical Data
Anticipated data for 1L EGFR exon 20 monotherapy cohort
NSCLC with EGFR exon 20 mutations (1L)source ↗
▲Dose Finding UpdateRinzimetostatTrial
Dose optimization data presented; RP3D selected as 400 mg once daily rinzimetostat
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆Oral PresentationPresentation
Conference call and webcast to discuss enozertinib data at ESMO Asia Congress
◆Oral PresentationORIC-114Presentation
Enozertinib Phase 1b data presented at ESMO Asia Congress 2025
NSCLC with EGFR exon 20 mutationssource ↗
◆Late-BreakerORIC-114Presentation
Proffered paper oral presentation of enozertinib in EGFR exon 20 mutant NSCLC at ESMO Asia 2025
EGFR exon 20 mutant NSCLCsource ↗
◆Oral PresentationORIC-114Presentation
Oral presentation at ESMO Asia Congress 2025
NSCLC with EGFR exon 20 mutationssource ↗
◆Poster PresentationORIC-114Presentation
Poster presentation of Phase 1b data for enozertinib in NSCLC with HER2 exon 20 mutations at ESMO Asia Congress 2025
NSCLC with HER2 exon 20 mutationssource ↗
◆Late-BreakerORIC-114Presentation
Mini-oral presentation of enozertinib in previously treated EGFR atypical mutant NSCLC at ESMO Asia 2025
EGFR atypical mutant NSCLCsource ↗
Past FDA Catalysts and PDUFA Decisions
How ORIC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | ORIC-114 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 22%
Micro Cap(rank 145 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rinzimetostat Small moleculeNCT07723248 | Metastatic Castration Resistant Prostate Cancer | Phase 3 | RECRUITING | 600 | Sep 1, 2030 | ||||||
| Rinzimetostat Small moleculeNCT05413421 | Metastatic Prostate Cancer | Phase 1 | RECRUITING | 275 | Apr 1, 2028 | ||||||
| ORIC-114 Small moleculeNCT06816992 | Solid Tumors | Phase 1 | RECRUITING | 426 | Dec 1, 2027 | ||||||
| ORIC-533 Small moleculeCompletedNCT05227144 | Relapsed or Refractory Multiple Myeloma | Phase 1 | COMPLETED | 31 | Mar 3, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every ORIC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Enozertinib | NSCLC | Phase 1b | 2026-10-23 | systemic ORR: 84%; intracranial ORR: 70%; brain metastases: 65%; previously untreated brain metastases: 46%Read More | ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 TrialRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Piscitelli DominicOfficer (Chief Financial Officer) | Option | 14,000 83,828 held | $4.36 | 10/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ORIC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 3.5 % (-2.8 %) | 72.87 M | 6.73 M |
ORIC Institutional Ownership Trends
ORIC Short Interest
Shares sold short, counted twice a month.
23.92%
Short % of Float
of tradable shares sold short
16.3M
Shares Sold Short
-6.9% vs prior count
9.9 High
Days to Cover
trading days of normal volume to buy every short share back
1.7M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ORIC ranks across every disease it competes in
Competitive Position is a premium feature
See how ORIC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialORIC News
ORIC▼ -32.7%today
ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026
ORIC Pharmaceuticals presented promising preclinical data on rinzimetostat at ESMO Congress 2026. The data suggests that rinzimetostat enhances sensitivity to androgen receptor inhibition in prostate cancer. It maintains effectiveness against resistance mutations and shows no signs of tumorigenesis in toxicology studies. The findings support its ongoing evaluation in the Himalayas-1 Phase 3 trial.
Read more →ORIC▼ -32.7%today
ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial
ORIC Pharmaceuticals presented promising data for enozertinib at ESMO Congress 2026, showing an 84% confirmed systemic objective response rate (ORR) in first-line NSCLC patients with EGFR atypical mutations. The drug also demonstrated a 70% confirmed intracranial ORR. The company plans to initiate a global Phase 3 trial in early 2027.
Read more →ORICORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026
ORIC Pharmaceuticals will host a conference call and webcast on October 23, 2026, to discuss clinical data from their Phase 1b trial of enozertinib for first-line NSCLC patients with EGFR atypical mutations. Dr. Joshua Sabari will present insights on the drug's potential. The event coincides with the ESMO Congress 2026 in Madrid.
Read more →ORICORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
ORIC Pharmaceuticals has partnered with Cancer Research UK to develop ORIC-259, a first-in-class small molecule mRNA degrader targeting CIP2A. Cancer Research UK will fund and manage the early clinical development of ORIC-259, which has shown promising preclinical results. ORIC retains the option to reacquire rights to the therapy after Phase 1/2 data is available.
Read more →ORICORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals announced the grant of stock options and restricted stock units to six new non-executive employees as part of its 2022 Inducement Equity Incentive Plan. The grants, totaling 161,550 stock options and 26,850 restricted stock units, are contingent on continued employment. This move aligns with Nasdaq regulations and reflects ORIC's commitment to attracting talent.
Read more →ORICORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals will participate in several investor conferences in September 2026, including the Wells Fargo 21st Annual Healthcare Conference, the 2026 Cantor Global Healthcare Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference. Management will engage in fireside chats and one-on-one meetings. Webcasts of these discussions will be accessible on the company's website.
Read more →ORIC▲ +27.1%on this news
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
ORIC Pharmaceuticals reported its Q2 2026 financial results, highlighting the initiation of the Himalayas-1 global Phase 3 trial for mCRPC. The company has entered a collaboration with Bayer for darolutamide and anticipates updates on rinzimetostat and enozertinib in the second half of 2026. With approximately $388 million in cash, ORIC expects to sustain operations through 2028.
Read more →ORICORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
ORIC Pharmaceuticals announced three poster presentations at the ESMO Congress 2026, showcasing data from ongoing clinical trials. The presentations will cover enozertinib's Phase 1b trial in NSCLC and rinzimetostat's Phase 3 study design in mCRPC. Full abstracts will be available on October 19, 2026.
Read more →ORIC▲ +5.6%on this newsshared move
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
ORIC Pharmaceuticals has launched the Himalayas-1 global Phase 3 trial for rinzimetostat in patients with metastatic castration-resistant prostate cancer (mCRPC). This trial, supported by a collaboration with Bayer, aims to evaluate rinzimetostat in combination with darolutamide. The study will enroll approximately 600 patients across 25 countries, focusing on radiographic progression-free survival as the primary endpoint.
Read more →ORICORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals announced that its management team will attend two major investor conferences in June. The company plans to participate in the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9. Executives will hold fireside chats and one-on-one meetings with investors at both events. Webcasts of these discussions will be available on the company website.
Read more →ORICORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
ORIC Pharmaceuticals announced the grant of 216,000 stock options and 35,000 restricted stock units to four new non-executive employees as part of its 2022 Inducement Equity Incentive Plan. These grants are intended to incentivize retention and were approved by the Compensation Committee in compliance with Nasdaq regulations. The stock options will vest over time, contingent on continued employment.
Read more →ORICORIC Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
ORIC Pharmaceuticals reported strong financial results for Q1 2026, announcing the selection of rinzimetostat's recommended Phase 3 dose for the Himalayas-1 trial in post-abiraterone mCRPC. Promising early data indicates rinzimetostat's potential best-in-disease profile and a favorable safety profile compared to standard therapies. The company maintains robust cash reserves, enabling operations into 2028, with significant updates anticipated for rinzimetostat and enozertinib in the latter half of 2026.
Read more →ORIC▲ +5.1%on this newsshared move
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals presented promising preclinical data on rinzimetostat at the 2026 AACR Annual Meeting. The data highlights rinzimetostat's potential to inhibit PRC2, a key mechanism in prostate cancer treatment resistance. The findings suggest that rinzimetostat could enhance the efficacy of androgen receptor-targeted therapies across various prostate cancer models.
Read more →ORIC▼ -41%on this newsshared move
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
ORIC Pharmaceuticals has selected rinzimetostat 400 mg once daily as the recommended Phase 3 dose in combination with darolutamide for the Himalayas-1 global trial in metastatic castration-resistant prostate cancer (mCRPC). The trial is set to begin in the first half of 2026, with early data indicating a strong safety profile and promising efficacy compared to existing therapies. The company aims to address a significant market need for effective treatments in this patient population.
Read more →About Oric Pharmaceuticals, Inc.
Headquarters240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next ORIC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime